Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies

References

• Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst. 18,769–778 (1957).
   PubMed Web of Science ®Google Scholar
• Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. EngL Med. 343(11), 750–758 (2000).
   PubMed Web of Science ®Google Scholar
• •Provides evidence for the tumor protective effect of GVHD in solid malignancy.
   Google Scholar
• Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft versus host disease in human recipients of allogeneic-marrow grafts. N Engl. J. Med. 300 (19), 1068–1073 (1979).
   Google Scholar
• Phelps RIVI, Smith DK, Heilig CM et al. Cancer incidence in women with or at risk for HIV. Int. Cancer 94 (5), 753–757 (2001).
   Google Scholar
• Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin. Oncol 27(4), 442–453 (2000).
   Google Scholar
• Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am. J. Med. Sci. May, 487–511 (1893).
   Google Scholar
• Bodey B, Bodey B, Jr, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. AntiCancer Res. 20(4), 2665–2676 (2000).
   PubMed Web of Science ®Google Scholar
• Old U. Immunotherapy for cancer. Sci. Am. 275(3), 136–143 (1996).
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM. Immunity against solid tumors? Int.j Cancer 93(1), 1–5 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 411(6835), 380–384 (2001).
   PubMed Web of Science ®Google Scholar
• Srivastava PK. Immunotherapy of human cancer: lessons from mice. Nat. ImmunoL 1(5), 363–366 (2000).
   PubMed Web of Science ®Google Scholar
• Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T-lymphocytes. Ann. Rev ImmunoL 12,337–365 (1994).
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495–497 (1975).
   PubMed Web of Science ®Google Scholar
• Hamann PR, Hinman LM, Hollander I et al. Gemtuzumab ozogamicin, a potent and selective antiCD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Biocopjug. Chem. 13(1), 47–58 (2002).
   Google Scholar
• Gordon LI, Wilzig TE, Wiseman GA et al. Yttrium 90 ibriturnomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin. OncoL 29(1 Suppl. 2), 87–92 (2002).
   Google Scholar
• Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high-and low-grade non-Hodgkin's lymphomas: a multicenter Phase I/II study. Ann. HematoL 81(1), 26–32 (2002).
   Google Scholar
• Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: Ongoing and future clinical development. Semin. OncoL 29(1 Suppl. 2), 105–112 (2002).
   Google Scholar
• Yip YL, Ward R. AntiErbB-2 monoclonal antibodies and ErbB-2 directed vaccines. Cancer ImmunoL Immunother. 50(11), 569–587 (2002).
   Google Scholar
• Hall, SS. A Commotion in the Blood: Life, Death and the Immune System. Henry Holt and Company, Inc., New York, NY, USA (1997).
   Google Scholar
• •Historical summary of the cancer immunology field.
   Google Scholar
• Gastman BR, Johnson DE, Whiteside TL, Rabinowich H. Tumor-induced apoptosis of T-lymphocytes: elucidation of intracellular apoptotic events. Blood 95(6), 2015–2023 (2000).
   Google Scholar
• Natali PG, Nicotra MR, Bigotti A et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl Acad. Sci. USA 86(17), 6719–6723 (1989).
   Google Scholar
• Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glirricher LH. Constitutive expression of B7 restores irnmunogenicity of tumor cells expressing truncated major histocompatiblity complex class II molecules. Proc Natl. Acad. Sci. USA 90(12), 5687–5690 (1993).
   Google Scholar
• Rosenberg SA. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer Sci. Am. 6 (Suppl. 1), S2-7 (2000).
   Google Scholar
• Liu HM, Newbrough SE, Bhatia SK, Dahle CE, Krieg AM, Weiner GJ. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 92(10), 3730–3736 (1998).
   Google Scholar
• Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Ann. Rev ImmunoL 18,767–811 (2000).
   PubMed Web of Science ®Google Scholar
• Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Ann. Rev ImmunoL 18,245–273 (2000).
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of DC-based vaccines.
   Google Scholar
• Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-call proliferation, which is reversible by IL-2. Nature Med. 4(1), 43–49 (1998).
   Google Scholar
• Owls RE Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In: Cancer: Principles & Practice of Oncology (Volume 1). DeVita VT, Jr, Hellman S, Rosenberg SA (Eds), Lippincott-Ravin Publishers, Philadelphia PA/New York, NY, USA, 5th Edition, 1502–1539 (1997).
   Google Scholar
• Berek JS, Bertelsen K, du Bois A et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann. OncoL10 (Suppl. 1), 87–92 (1999).
   Google Scholar
• Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. OncoL 8(10), 963–968 (1997).
   Google Scholar
• Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. .1. Clin. Oncol. 18(17), 3093–3100 (2000).
   Google Scholar
• Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Clin. Oncol. 16(10), 3345–3352 (1998).
   Google Scholar
• van der Burg MEL, de Wit R, van Putten WLJ et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br. .1. Cancer86, 19–25 (2002).
   Google Scholar
• McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl. .1. Med. 334(1), 1–6 (1996).
   Google Scholar
• •The definitive study establishing the role of taxanes in the management of ovarian cancer.
   Google Scholar
• Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. .1. Nat/ Cancer Inst. 92(9), 699–708 (2000).
   Google Scholar
• Vergote IB, De Weyer I, Decloedt J, Tjalma W, Van Gramberen M, van Dam P. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin. Oncol. 27(3 Suppl. 7), 31–36 (2000).
   Google Scholar
• Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl. .1. Med. 309(15), 883–887 (1983).
   Google Scholar
• Bast RC Jr, Siegal FP, Runowicz C et al. Elevation of serum CA125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol. Oncol. 22(1), 115–120 (1985).
   Google Scholar
• Tuxen MK, Soletormos G, Dombernowsky P Tumor markers in the management of patients with ovarian cancer. Cancer Treat. Rev 21(3), 215–245 (1995).
   Google Scholar
• Sartori S, Nielsen I, Tassinari D, Trevisani L, Abbacsiano V, Malacarne P Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology 61 (3), 192–196 (2001).
   Google Scholar
• van Zanten-Przybysz I, Molthoff CF, Roos JC et al. Radioimmunotherapy with intravenously administrated131I-labled chimeric monoclonal antibody M0v18 in patients with ovarian cancer. J. Nucl. Med 41(7), 1168–1176 (2000).
   Google Scholar
• Correa I, Plunkett T. Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines. Breast Cancer Res. 3(6), 399–403 (2001).
   Google Scholar
• Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. .1. Clin. Invest. 107(4), 477–484 (2001).
   Google Scholar
• Murray JL, Przepiorka D, Ioannides CG. Clinical trials of HER-2/neu-specific vaccines. Semin. Oncol. 27(6 Suppl. 11), 71–75 (2000).
   Google Scholar
• Zhao X, Wei YQ, Peng ZL. Induction of T- cell responses against autologous ovarian tumors with whole cell lysate-pulsed dendritic cells. Immunol. Invest. 30(1), 33–45 (2001).
   Google Scholar
• Santin AD, Hermonat PL, Ravaggi A et al. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T-lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am. J. Obstet. Gynecol 183 (3), 601–609 (2000).
   Google Scholar
• Collinet P, Lanvin D, Vereecque R, Quesnes B, Querleu D. Gene therapy and ovarian cancer: update of clinical trials. .1. Gynecol. Obstet. Biol. Reprod. Ads) 29(6), 532–537 (2000).
   Google Scholar
• Epenetos AA, Hird V, Lambert H, Mason P, Coulter C. Long-term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int. .1. Gynecol. Cancer 10(S1), 44–46 (2000).
   Google Scholar
• Sabbatini PJ, Kudryashov V, Ragupathy G et al. Immunization of ovarian cancer patients with a synthetic Lewis (y)-protein conjugate vaccine: a Phase 1 trial. Int. .1. Cancer87(1), 79–85 (2000).
   Google Scholar
• Berd D. Autologous, hapten-modified vaccine as a treatment for human cancers. Vaccine 19(17-19), 2565–2570 (2001).
   PubMed Web of Science ®Google Scholar
• Freedman RS, Kudelka AP, Kavanagh JJ et al. Clinical and biological effects of ip. injections of recombinant interferon-gamma and recombinant interleukin-2 with or without tumor-infiltrating lymphocytes in patients with ovarian cancer or peritoneal carcinoma. Clin. Cancer Res. 6(6), 2268–2278 (2000).
   Google Scholar
• Mahe MA, Fumoleau P, Fabbro M et al. A Phase II study of ip. radioimmunotherapy with 131Iodine-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin. Cancer Res. 5(10 Suppl), 3249s-3253s (1999).
   Google Scholar
• Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, Longenecker BM. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue and immunization with Theratope STn-KLH cancer vaccine. .1. Immunother 22(1), 54–66 (1999).
   Google Scholar
• Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96(9), 3102–3108 (2000).
   PubMed Web of Science ®Google Scholar
• Agus DB, Bunn PA Jr, Franklin W, Garcia M, Ozols RE HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer and ovarian cancer. Semin. Oncol 27(6 Suppl. 11), 53–63 (2000).
   Google Scholar
• Peoples GE, Anderson BW, Lee TW et al. Vaccine implications of folate binding protein, a novel cytotoxic T-Iymphocyte-recognized antigen system in epithelial cancers. Clin. Cancer Res. 5 (12), 4214–4223 (1999).
   Google Scholar
• Gong J, Nikrui N, Chen D et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. .1. Immunol 165(3), 1705–1711 (2000).
   Google Scholar
• Miles DW, Taylor-Papadimitriou J. Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma. Pharmacol. The,: 82(1), 97–106 (1999).
   Google Scholar
• Santin AD, Ioli GR, Hiserodt JC et al. Development and in vitro characterization of a GM-CSF secreting human ovarian carcinoma tumor vaccine. Int. .1. Gynecol. Cancer5 (6), 401–410 (1995).
   Google Scholar
• Mallmann P Tumor vaccination. Hybridoma 14(2), 187–190 (1995).
   Google Scholar
• Maruiic-Galekc S, Maruiic M, Pokric B. Cellular immune response to the antigen administered as an immune complex in vivo. Immunology75, 325–329 (1992).
   Google Scholar
• Manca F, Fenoglio D, Kunkl A, Cambiaggi C, Sasso M, Celada E Differential activation of T-cell clones stimulated by macrophages exposed to antigen complexed with monoclonal antibodies. J. ImmunoL 140, 2893–2898 (1988).
   PubMedGoogle Scholar
• Manca F, Fenoglio D, Li Pira G, Kunkl A, Celada E Effect of antigen/antibody ratio on macrophage uptake, processing and presentation to T-cells of antigen complexed with polyclonal antibodies. J. Exp. Med. 173, 37–48 (1991).
   PubMed Web of Science ®Google Scholar
• Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B-cells. Exp. Med. 173, 487–489 (1991).
   PubMed Web of Science ®Google Scholar
• Rock KL, Benacerraf B, Abbas AK. Antigen presentation by hapten-specific B-lymphocytes. I Exp. Med. 160, 1102–1113 (1984).
   Google Scholar
• Lanzavecchia A. Antigen-specific interaction between T and B-cells. Natum 314, 537–539 (1985).
   PubMed Web of Science ®Google Scholar
• Steinman RIVI, Cohn ZA. The interaction of particulate horseradish peroxidase (HRP)-anti-HRP immune complexes with mouse peritoneal macrophages in vitro. J. Cell Biol. 55, 616–634 (1972).
   PubMedGoogle Scholar
• Coccia MA, Brams P High titer, prostate specific antigen-specific human IgG production by hu-PBL-SCID mice immunized with antigen-mouse IgG2a complex-pulsed autologous dendritic cells. ImmunoL 161, 5772–5780 (1998).
   Web of Science ®Google Scholar
• Tony H-P, Parker DC. Major histocompatibility complex-restricted, polyclonal B-cell responses resulting from helper T-cell recognition of anti-immunoglobulin presented by small B-lymphocytes. j Exp. Med. 161, 223–241 (1985).
   Google Scholar
• Regnault A, Lankar D, Lacabanne V et al. Fcy receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I restricted antigen presentation after immune complex internalization.," Exp. Med. 189, 371–380 (1999).
   Google Scholar
• •Early demonstration of the ability of antibodies to promote class I and class II antigen cross-presentation.
   Google Scholar
• Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T-cell antigenic determinants. Ann. Rev ImmunoL 11, 729–766 (1993).
   PubMed Web of Science ®Google Scholar
• Von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur. J. Cancer 32A, 1325–1331 (1996).
   Google Scholar
• Schultes BC, Agopsowicz K, Baum RP et al. Induction of CA125-specific B and T-cell responses in MAb-B43.13 injected patients depends on complex formation of the MAb with circulating antigen. FASEB 14, 53.24, (2000).
   Google Scholar
• Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Ann. Rev Immunol 19, 47–64 (2001).
   PubMed Web of Science ®Google Scholar
• •Comprehensive summary of challenges to stimulating clinically relevant immunity.
   Google Scholar
• Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Ann. Rev ImmunoL 15, 821–850 (1997).
   PubMed Web of Science ®Google Scholar
• Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 276, 243–246 (1995).
   Google Scholar
• Pfeifer JD, Wick MJ, Roberts RL, Finlay K, Normark SJ, Harding CV. Phagocytic processing of bacterial antigens for class I MHC presentation to T-cells. Nature 361, 359–362 (1993).
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A. Mechanisms of antigen uptake for presentation. CUIT: Opin. ImmunoL 8, 348–354 (1996).
   Google Scholar
• Schultes BC, Agopsowicz K, Kuzma M, Nicodemus CF, Noujaim AA, Mann DL. Antibody-antigen immune complexes allow for efficient MHC class I and II-restricted antigen presentation and maturation of dendritic cells: a novel strategy for cancer immunotherapy. Proc. Am. Assoc. Cancer Res. 42, 276, 1486 (2001).
   Google Scholar
• Ravetch JV, Bolland S. IgG Fc receptors. Ann. Rev ImmunoL 19, 275–290 (2001).
   PubMed Web of Science ®Google Scholar
• Qi W, Liu D, Xu D et al. Factors to consider in antibody-based immunotherapy of cancer. Proc. Am. Assoc. Cancer Res. 41, 290, 1847 (2000).
   Google Scholar
• Noujaim AA, Schultes BC, Baum RE Madiyalakan R. Induction of CA 125-specific B and T-cell responses in patients injected with MAb-B43.13-evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother. Radiopharm. 16(3), 187–203 (2001).
   Google Scholar
• •Comprehensive summary of immune responses induced by MAb-B43.13 administration.
   Google Scholar
• Bolle M, Niesen A, Korz W et al. Possible role of antiCA125 monoclonal antibody B43.13 (OvaRex) administration in long-term survival of relapsed ovarian cancer. Proc. ASCO 19, 476a (2000).
   Google Scholar
• Ehlen T, Gordon A, Fingert H et al. Adjuvant treatment with monoclonal antibody, OvaRex® MAb-B43.13 (0V) targeting CA125, induces robust immune responses associated with prolonged time to relapse (1-1R) in a randomized, placebo-controlled study in patients (pts) with advanced epithelial ovarian cancer (E0C). Proc. ASCO 21,99 (2002) (abstract in press).
   Google Scholar
• Berek J, Ehlen T, Gordon A et al. Interim analysis of a double-blind study of OvaRex Tm MAb B43.13 (0V) versus placebo (PBO) in patients with ovarian cancer. Proc. ASCO 20, 210a (2001).
   Google Scholar
• Gordon A, Stringer A, Edwards R, Whiteside T, Fingert H, Schultes B. Clinical and immunologic outcomes of patients with recurrent epithelial ovarian cancer treated with OvaRex® MAb and chemotherapy. GynecoL OncoL 84, 501 (2002).
   Google Scholar
• Ehlen T, Whiteside T, Schultes B, Siemens M, Noujaim AA, Nicodemus CE Induction of tumor protective immunity utilizing the CA125 specific monoclonal, OvaRex® MAb-B43.13, in a cohort of patients with advanced recurrent ovarian cancer. GynecoL OncoL 80(2), 310 (2001).
   Google Scholar
• Wagner U, Köhler S, Reinartz S et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res. 7 (5), 1154–1162 (2001).
   Google Scholar
• Schultes BC, Tolcher A, Agopsowicz K. A Phase I study of antiMUC-1 antibody BrevarexTm MAb-AR20.5 in patients with MUC1 expressing malignancies. Blood 96(11), 618a (2000).
   Google Scholar
• Berlyn KA, Schultes B, Leveugle B, Noujaim AA, Alexander RB, Mann DL. Generation of CD4+ and CD8+ T-lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/ antibody) complexes. Clin. ImmunoL 101(3), 276–283 (2001).
   Google Scholar
• Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T-cells by dendritic cells. J. Exp. Med. 195(1), 125–133 (2002).
   Google Scholar
• •Demonstration that antibody-induced cross-presentation enhances generation of tumorcidal lymphocytes by DCs.
   Google Scholar
• Foon KA, John WJ, Chakraborty M et al Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin. Cancer Res. 3(8), 1267–1276 (1997).
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Cheung NV Phase II trial of the antiGD2 monoclonal antibody 3F8 and granulocyte- machrophage colony-stimulating factor for neuroblastoma. j Clin. Oncol 19(22), 4189–4194 (2001).
   Google Scholar
• •Latest report from a series of neuroblastoma patients followed at Memorial Sloan Kettering treated with an antiGD2 antibody.
   Google Scholar
• Frodin JE, Faxas ME, Hagstrom B et al. Induction of antiidiotypic (ab2) and antiantiidiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (abl). Relation to the clinical outcome-an important antitumoral effector function? Hybridoma 10(4), 421–431 (1991).
   Google Scholar
• Gruber R, van Haarlem 1,J, Warnaar SO, Holz E, Riethmuller G. The human antimouse immunoglobulin response and the antiidiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody C017-1A. Cancer Res. 60(7), 1921–1926 (2000).
   Google Scholar